BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-95298177 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-95298177\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04662580-11222@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:JNJ-95298177: Phase 1 readout est. (NCT04662580)
DESCRIPTION:JNJ-95298177\, phase 1\, Prostate Cancer.\nStudy: ARX517/JNJ-95
 298177 as Monotherapy or Combination Therapy in Subjects With Metastatic P
 rostate Cancer\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/jnj-95298177#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04662580
URL:https://assetmemo.bio/drug/jnj-95298177#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082920-11222@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:JNJ-95298177: Phase 1 readout est. (NCT07082920)
DESCRIPTION:JNJ-95298177\, phase 1\, Prostate Cancer.\nStudy: A Study of JN
 J-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Canc
 er\nEstimated primary completion: 30 November 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/jnj-95298177#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07082920
URL:https://assetmemo.bio/drug/jnj-95298177#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
